Related Experiment Videos
Recent developments in 99mTc and 123I-radiopharmaceuticals for SPECT imaging
1Department of Radiology, The University of Texas Southwestern Medical Center, Dallas 75235.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
|January 1, 1991
Summary
High-purity iodine-123 (123I) and technetium (99mTc) agents are advancing medical imaging. These radiopharmaceuticals improve assessments of heart and brain function, and disease detection.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
- Medical imaging
Background:
- High radionuclidic purity of iodine-123 (123I) enables new radiopharmaceutical development.
- Advances in technetium (99mTc) chemistry have led to novel imaging agents.
- Monoclonal antibodies labeled with 99mTc show potential in various diagnostic applications.
Purpose of the Study:
- To discuss recent developments in 123I and 99mTc agents.
- To highlight their applications in myocardial and brain imaging.
- To review their use in assessing metabolic and functional processes.
Main Methods:
- Review of recent advancements in radiopharmaceutical chemistry for 123I and 99mTc.
- Discussion of applications in myocardial fatty acid metabolism and neuronal activity assessment.
- Exploration of receptor, antibody, and perfusion imaging techniques.
Main Results:
- 123I-based agents are effective for myocardial and brain imaging.
- Novel 99mTc agents are developed for myocardial, cerebral perfusion, and renal studies.
- 99mTc-labeled monoclonal antibodies show promise for detecting neoplastic lesions, infarcts, and thrombi.
Conclusions:
- Recent developments in 123I and 99mTc agents significantly enhance diagnostic capabilities in nuclear medicine.
- These radiopharmaceuticals offer improved methods for evaluating cardiac and neurological conditions.
- Further research and application of these agents are expected to advance medical imaging.